Jiudian Hongyang, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had registration no. of Polaprezinc (Y20230000678) from NMPA recently.

Polaprezinc is a new generation of anti-gastric ulcer drug, which is the first zinc-containing compound used in the clinic, has a high affinity with the gastric mucosa, could be attached for a long period of time, through the antioxidant effect, and membrane stabilization, to achieve direct protection of the cell, and has the role of promoting wound healing through tissue repair. Polaprezinc is a chelate of L-creatinine and zinc. In addition to the advantages of zinc, the L-creatinine contained in polaprezinc can also promote the regeneration of granulation tissue and the healing of ulcers, and can be used for peptic ulcers and Hp eradication. Polaprezinc has been widely used in Japan since 1994, and clinical applications over the years have confirmed that polaprezinc is an effective and safe anti-gastric ulcer drug.

Jiudian HongYang has 79 APIs and 82 excipients with registration numbers. The company will uphold the concept of providing high-end, high-quality APIs and excipients products and services to the market to embrace more and broader opportunities for cooperation.